Wantstats
Company ProfilePremium

Merck & Co., Inc.

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Merck & Co., Inc. - Healthcare showcase

Year Founded & Workforce

1891

69,000 Employees

Industry

Healthcare

Services

ChemotherapyPEGylated DrugsAllergic RhinitisPain Management
M

Merck & Co., Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Merck & Co., Inc. Overview

Company Headquarters: New Jersey, US

Founded: 1891

Workforce: ~69,000

Company Working: Merck & Co., Inc. (Merck) is a leading global biopharmaceutical company that develops prescription medicines, vaccines, biologic therapies, and animal health products. The company operates in more than 140 countries to deliver innovative health solutions. It operates through pharmaceutical, animal health, and healthcare services segment. The pharmaceutical segment includes human health pharmaceutical and vaccine products. The animal health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment, and control of diseases in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The healthcare services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients.

Strategy

Merck focuses on developing a diversified product portfolio by the innovation and development of products, thus delivering integrated solutions to large healthcare customers. It is engaged in making externally sourced programs a more significant component of its pipeline strategy, with a strong focus on internal research and external alliance through collaborations. It aims to increase its product portfolio via R&D investments. The company is focused on acquisitions and partnerships with established players. The company also emphasizes specialty products in healthcare, life science, and performance materials.

Company Snapshot

$41,518M

Revenue

69,000

Employees

1891

Founded

New Jersey, US

Headquarters

SWOT Analysis

Strengths

  • Strong R&D base
  • Customer loyalty and brand visibility
  • Improved performance of the pharmaceuticals segment
  • Strong R&D investments
  • Global presence
  • Well-known industry associations
  • Trusted partnerships and associations with medical service agencies
  • Well recognized brand
  • Strategic collaborations and partnerships to achieve the company’s goals
  • Skilled workforce

Weaknesses

  • High cost of products
  • Limited product range for the glioblastoma treatment
  • Over dependence on the pharmaceutical segment
  • Significant reliance on key products
  • Product recalls dulling the brand image
  • High R&D expenditure
  • Large business segment is difficult to handle
  • Limited product range for the allergic rhinitis market
  • Limited PEGylated products

Opportunities

  • Mergers & acquisitions
  • Product launches
  • Encourage inventive concepts and solutions
  • New product launches
  • Increase in the demand for body building drugs
  • Innovative product development

Threats

  • Intense rivalry with other key players
  • Issues regarding outsourcing of products
  • Intense competition
  • Industry amalgamation intensify competition
  • Reimbursement policies
  • Patent expiration
  • Stringent government regulatory control

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
–AcquisitionMerck entered into a definitive agreement to acquire Peloton Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. With this acquisition, the company focuses on the expansion of its oncology business.
–Product DevelopmentPeloton Therapeutics, Inc. is identifying the maximum tolerated dose (MTD) of PT2977 Tablets in patients with glioblastoma multiforme. Currently, the study is in Phase 1. This study is being carried out to expand its product portfolio.
March 2019CollaborationMerck entered into a collaboration with strategic Eisai Co. for the development and commercialization of Lenvima oncology products.
June 2018ApprovalThe company received FDA approval for Keytruda for the treatment of refractory primary mediastinal large B-cell lymphoma.
–AgreementMerck & Co., Inc. and Perrigo entered into an agreement over product rights of Nasonex for the US. This enabled the company to expand its product portfolio.
March 2019AcquisitionMerck acquired Immune Design. Immune Design deals with immunotherapy products. Hence, these products have also been added to the immunotherapy related products range of Merck.
June 2018AcquisitionMerck acquired Viralytics Limited, an Australian company. The core business of Viralytics Limited is related to oncolytic immunotherapy treatments for a range of cancers. This business acquisition has contributed to strengthening Merck’s product range and related markets.

Product Offering

  • Merck & Co., Inc.
    • Chemotherapy
    • PEGylated Drugs
    • Allergic Rhinitis
    • Pain Management

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 41,518 Mn in 2020 to USD 59,283 Mn in 2022.
Merck & Co., Inc. — By Business Segment
Series (USD Mn)202020212022
Sales41,51848,70459,283
R&D Expenses13,39712,24513,500

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →